Of note, plasma from CLL patients has been shown to increase CXCR2 expression in neutrophils, thus allowing CXCL-8-mediated activation; however, the plasma factors responsible for these upregulatory effects remain unknown (58). The gene discussed is CXCR2; the disease is B-cell chronic lymphocytic leukemia.